Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
09:25am, Wednesday, 29'th Oct 2025
LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and fuel long-term growth.
Lilly and Walmart launch first retail pick-up option for weight-loss drug
07:11am, Wednesday, 29'th Oct 2025
Eli Lilly and Walmart said on Wednesday they are partnering to expand access to single-dose vials of Lilly's weight-loss drug Zepbound, which will be offered for pick-up at Walmart pharmacies nationwi
LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound
07:00am, Wednesday, 29'th Oct 2025
Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials Strategic collaboration marks the first time patients us
1 Undervalued Growth Stock Down 8% to Buy Before 2026
08:10pm, Tuesday, 28'th Oct 2025
Eli Lilly's performance over the past year hasn't been as strong as usual. The company's growth prospects justify its higher-than-average valuation.
Lilly partners with Nvidia on AI supercomputer to speed up drug development
02:31pm, Tuesday, 28'th Oct 2025
Eli Lilly said on Tuesday it was collaborating with Nvidia to build a supercomputer to help with drug discovery and shorten development cycles, getting medicines to people faster.
Eli Lilly, Nvidia partner to build supercomputer, AI factory for drug discovery and development
02:30pm, Tuesday, 28'th Oct 2025
Eli Lilly and Nvidia are partnering to build what the companies call the pharmaceutical industry's "most powerful" supercomputer and so-called AI factory to help accelerate drug discovery and developm
Eli Lilly Partners With Nvidia to Build AI Supercomputer for Drug Discovery
02:30pm, Tuesday, 28'th Oct 2025
The drugmaker hopes an Nvidia-chip powered supercomputer will help it find new drugs and accelerate lengthy R&D timelines.
New AI capabilities will help scientists identify, optimize and validate new molecules Additional applications include manufacturing, medical imaging and enterprise AI agents INDIANAPOLIS , Oct. 28,
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings
10:40am, Tuesday, 28'th Oct 2025
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
Is It Worth Investing in Lilly (LLY) Based on Wall Street's Bullish Views?
10:30am, Tuesday, 28'th Oct 2025
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing the previous two-injection regimen Omvoh single-injection dosing will be available for U.S. patien
Lilly declares fourth-quarter 2025 dividend
02:00pm, Monday, 27'th Oct 2025
INDIANAPOLIS , Oct. 27, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common
Baron Health Care Fund Q3 2025 Top Contributors And Detractors
01:27pm, Monday, 27'th Oct 2025
Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagno
BDF-GESTION Trims Its Eli Lilly (LLY) Stake by 4,149 Shares
12:36pm, Monday, 27'th Oct 2025
BDF-GESTION sold 4,149 shares of Eli Lilly and Company; Transaction value was $3.1 million Transaction represents 0.37% of BDF-GESTION's 13F reportable assets under management Post-trade stake: 19,949
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
12:06pm, Monday, 27'th Oct 2025
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
